The antitumour effect of the somatostatin analogue TT-232 depends on the treatment regimen

Miguel Tejeda, D. Gaál, O. Csuka, Axel Ullrich, Richárd Schwab, A. Pap, Anikó Horváth, G. Kéri

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The somatostatin analogue TT-232, containing a five residue ring structure, has a strong antitumour activity both in vitro and in vivo. This peptide has no effect on growth hormone (GH) release, but exhibits a remarkable tyrosine kinase inhibitory effect and induced apoptosis. We studied the effect of TT-232 in different routes of administration and treatment schedules on various types of mouse tumour models. The infusion treatment with inserted Alzet osmotic minipumps proved to be superior to both twice daily subcutaneous (s.c.) or intravenous (i.v.) injections in a 2 weeks period. In the case of S-180 tumour the infusion treatment resulted in 77-100% tumour growth inhibition and in 40-60% of mice long-term and tumour-free survivors. With the P-388sc tumour the infusion of TY-232 resulted in 20-40% of animals long-term and tumour-free survivors and in 76-100% tumour growth inhibition. In the very aggressive Colon-26 (C-26) and MXT, the TY-232 treatment resulted in 71-75% tumour growth inhibition and increased survival time by about 50%.

Original languageEnglish
Pages (from-to)155-162
Number of pages8
JournalCancer Detection and Prevention
Volume27
Issue number2
DOIs
Publication statusPublished - 2003

Fingerprint

Somatostatin
Neoplasms
Therapeutics
Growth
TT2-32
Subcutaneous Injections
Intravenous Injections
Protein-Tyrosine Kinases
Growth Hormone
Appointments and Schedules
Colon
Apoptosis
Peptides

Keywords

  • Anticancer drug therapy
  • Somatostatin analogue
  • Treatment schedule
  • TT-232

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

The antitumour effect of the somatostatin analogue TT-232 depends on the treatment regimen. / Tejeda, Miguel; Gaál, D.; Csuka, O.; Ullrich, Axel; Schwab, Richárd; Pap, A.; Horváth, Anikó; Kéri, G.

In: Cancer Detection and Prevention, Vol. 27, No. 2, 2003, p. 155-162.

Research output: Contribution to journalArticle

Tejeda, Miguel ; Gaál, D. ; Csuka, O. ; Ullrich, Axel ; Schwab, Richárd ; Pap, A. ; Horváth, Anikó ; Kéri, G. / The antitumour effect of the somatostatin analogue TT-232 depends on the treatment regimen. In: Cancer Detection and Prevention. 2003 ; Vol. 27, No. 2. pp. 155-162.
@article{0a40dae3b5f440a1864e6f1118e72e16,
title = "The antitumour effect of the somatostatin analogue TT-232 depends on the treatment regimen",
abstract = "The somatostatin analogue TT-232, containing a five residue ring structure, has a strong antitumour activity both in vitro and in vivo. This peptide has no effect on growth hormone (GH) release, but exhibits a remarkable tyrosine kinase inhibitory effect and induced apoptosis. We studied the effect of TT-232 in different routes of administration and treatment schedules on various types of mouse tumour models. The infusion treatment with inserted Alzet osmotic minipumps proved to be superior to both twice daily subcutaneous (s.c.) or intravenous (i.v.) injections in a 2 weeks period. In the case of S-180 tumour the infusion treatment resulted in 77-100{\%} tumour growth inhibition and in 40-60{\%} of mice long-term and tumour-free survivors. With the P-388sc tumour the infusion of TY-232 resulted in 20-40{\%} of animals long-term and tumour-free survivors and in 76-100{\%} tumour growth inhibition. In the very aggressive Colon-26 (C-26) and MXT, the TY-232 treatment resulted in 71-75{\%} tumour growth inhibition and increased survival time by about 50{\%}.",
keywords = "Anticancer drug therapy, Somatostatin analogue, Treatment schedule, TT-232",
author = "Miguel Tejeda and D. Ga{\'a}l and O. Csuka and Axel Ullrich and Rich{\'a}rd Schwab and A. Pap and Anik{\'o} Horv{\'a}th and G. K{\'e}ri",
year = "2003",
doi = "10.1016/S0361-090X(03)00022-9",
language = "English",
volume = "27",
pages = "155--162",
journal = "Cancer Epidemiology",
issn = "1877-7821",
publisher = "Elsevier BV",
number = "2",

}

TY - JOUR

T1 - The antitumour effect of the somatostatin analogue TT-232 depends on the treatment regimen

AU - Tejeda, Miguel

AU - Gaál, D.

AU - Csuka, O.

AU - Ullrich, Axel

AU - Schwab, Richárd

AU - Pap, A.

AU - Horváth, Anikó

AU - Kéri, G.

PY - 2003

Y1 - 2003

N2 - The somatostatin analogue TT-232, containing a five residue ring structure, has a strong antitumour activity both in vitro and in vivo. This peptide has no effect on growth hormone (GH) release, but exhibits a remarkable tyrosine kinase inhibitory effect and induced apoptosis. We studied the effect of TT-232 in different routes of administration and treatment schedules on various types of mouse tumour models. The infusion treatment with inserted Alzet osmotic minipumps proved to be superior to both twice daily subcutaneous (s.c.) or intravenous (i.v.) injections in a 2 weeks period. In the case of S-180 tumour the infusion treatment resulted in 77-100% tumour growth inhibition and in 40-60% of mice long-term and tumour-free survivors. With the P-388sc tumour the infusion of TY-232 resulted in 20-40% of animals long-term and tumour-free survivors and in 76-100% tumour growth inhibition. In the very aggressive Colon-26 (C-26) and MXT, the TY-232 treatment resulted in 71-75% tumour growth inhibition and increased survival time by about 50%.

AB - The somatostatin analogue TT-232, containing a five residue ring structure, has a strong antitumour activity both in vitro and in vivo. This peptide has no effect on growth hormone (GH) release, but exhibits a remarkable tyrosine kinase inhibitory effect and induced apoptosis. We studied the effect of TT-232 in different routes of administration and treatment schedules on various types of mouse tumour models. The infusion treatment with inserted Alzet osmotic minipumps proved to be superior to both twice daily subcutaneous (s.c.) or intravenous (i.v.) injections in a 2 weeks period. In the case of S-180 tumour the infusion treatment resulted in 77-100% tumour growth inhibition and in 40-60% of mice long-term and tumour-free survivors. With the P-388sc tumour the infusion of TY-232 resulted in 20-40% of animals long-term and tumour-free survivors and in 76-100% tumour growth inhibition. In the very aggressive Colon-26 (C-26) and MXT, the TY-232 treatment resulted in 71-75% tumour growth inhibition and increased survival time by about 50%.

KW - Anticancer drug therapy

KW - Somatostatin analogue

KW - Treatment schedule

KW - TT-232

UR - http://www.scopus.com/inward/record.url?scp=0037259824&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037259824&partnerID=8YFLogxK

U2 - 10.1016/S0361-090X(03)00022-9

DO - 10.1016/S0361-090X(03)00022-9

M3 - Article

VL - 27

SP - 155

EP - 162

JO - Cancer Epidemiology

JF - Cancer Epidemiology

SN - 1877-7821

IS - 2

ER -